Case report · 2 Mar 2023
Research articlePublished 3 May 2022
Differential Inhibitory Effects of Cytotoxic Agents on Lymphoma Cell Proliferation and Tumor Growth
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In the last few decades, many biomolecules obtained from nature exhibit great potential in antitumor application, some of them have made great contributions to clinical treatment. Ansamitocin P3 and paclitaxel are tubulin inhibitors while camptothecin is a Topo I inhibitor. These molecules are known to induce apoptosis of cancer cells and either has been used or show great potential in application of tumor targeted therapy. In this study, we investigated the roles and mechanisms of ansamitocin P3, paclitaxel and camptothecin in inducing apoptosis of human histolytic lymphoma U937 cells. CCK8 assay was performed on U937 cells and the results showed that ansamitocin P3 exhibits great antiproliferative activities with a half-maximal inhibitory concentration (IC 50) at 0.18 ± 0.04 nM, while the IC50 of camptothecin and paclitaxel was 25.09 ± 2.64 and 6.06 ± 1.24 nM respectively. Results of apoptosis analysis by flow cytometry indicated that both early and late apoptotic cells increased significantly after treated with above three biomolecules. Cell cycle analysis results suggested that ansamitocin P3 and paclitaxel arrested cells in the G2/M Phase, while camptothecin arrested cells in G2/M phase at low concentration but S phase at high concentration. Mechanistically, we have performed expression analysis using qRT-PCR and found that ansamitocin P3 and paclitaxel may induce apoptosis of cells by down regulating expression of PCNA and BCL-2, while cells treated with camptothecin showed upregulated P21 but down regulated BCL-2 expression. Moreover, to investigate the in vivo anti-tumor activity of ansamitocin P3, we have shown data in a xenograft tumor model that ansamitocin P3 greatly inhibited tumor growth with little side effect. Taken together, our results suggest the strongest antitumor activity of ansamitocin P3 on lymphoma U937 cells. Ansamitocin P3 has great potential in tumor targeted therapy.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 31 Aug 2021
The Cytotoxic Molecule Ansamitocin P-3 Suppresses Cell Proliferation and Tumor Growth in Lung Carcinoma
Research article · 30 Jan 2023
The Suppressive Effects of Cytotoxic Agents on Lymphoma Cell Proliferation and Tumor Growth
Conference abstract · 3 Nov 2014
Vasculogenic mimicry-forming tumor cells have increased resistance against cytotoxic agents in threedimensional tumor cell cultures
Case report · 2018
Coexisting B- Cell Lymphoma and Benign Mesenchymal Phospaturic Tumor: Debut as Acute Renal Failure Associated with Hypercalcemia and Hypophosphatemia
More from this journal
The newest in Health Science Journal.
Editorial · 31 Dec 2025
Energy-Boosting Nutrition: Fueling the Body for Optimal Performance and Vitality
Editorial · 31 Dec 2025
Digestive Balance: Maintaining a Healthy Gut for Optimal Digestion and Well-being
Editorial · 31 Dec 2025
Prebiotics: Exploring the Role of Dietary Components in Supporting Gut Health and Overall Wellness
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalHealth Science Journal
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Qiping Zheng”
- BylineArticles whose byline prints “Lichun Sun”
- BylineArticles whose byline prints “Mengli Yang”
- BylineArticles whose byline prints “Shilei Wang”
- BylineArticles whose byline prints “Ying Chen”
- BylineArticles whose byline prints “Xiaojing Zhang”
- BylineArticles whose byline prints “Chen Chen”
- BylineArticles whose byline prints “Songhai Shen”

